secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001213900-23-075473
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Nektar terminates collaboration agreement with Bristol-Myers Squibb for bempegaldesleukin
--------------------------------------------------------------------------------

- Parties entered letter agreement on Sept 6, 2023 to terminate the 2018 Strategic Collaboration Agreement.
- Collaboration covered development of bempegaldesleukin in combination with BMS's Opdivo (nivolumab).
- Global clinical development program for the combination was already ended in April 2022.
- Termination effective immediately per the letter agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023075473/0001213900-23-075473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023075473/ea184617-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-075473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer